Menu
Oncimmune
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
Healthcare: Diagnostics – cancer
School of Medicine
Profile
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
The technology is based on serum assays that detect auto-antibody formation to known cancer antigens with the clinical utility of early diagnosis of cancer.
This breakthrough is currently applied to lung cancer through the development of a blood test EarlyCDT®, but will be extended to the detection of other common cancers such as breast, colorectal, ovarian and prostate.
The company is based in customised laboratory and office space at Nottingham City Hospital, and began trading on AIM in May 2016.
News and press releases
Our sale of shares represents a significant return on our original investment in Oncimmune and the company is an exemplar of what can be done when a technology is successfully spun out from the University of Nottingham. It has been a pleasure to see Oncimmune grow into a leading early cancer detection company that is already saving lives and is on track to save many more. We look to the future with confidence as the company has the management and strategy in place to deliver value and we are delighted to retain a significant shareholding
Dr Andrew Naylor
Chief executive – Nottingham Technology Ventures
@OncimmuneECDT on Twitter
#BIO2022 We’re mid-way through the conference and our team is so excited to be back at BIO in person! Awesome sessions and lots of great discussions showcasing Oncimmune’expertise and our platform #ImmunoINSIGHTS #autoantibodies #biomarkers #clinicaltrials #immunooncology
Meet Oncimmune at BIO 2022 in San Diego June 13-16! #BIO2022 #LimitlessTogether https://bit.ly/3ufsmMh
Find our company in the partnering system and schedule a meeting. #ImmunoINSIGHTS #autoantibodies #biomarker #immunebiomarkers #clinicalresearch #immunotherapies #celltherapy
For today’s #FRIDAYREAD we would like to share a publication from @JanssenGlobal on next Generation Natural Killer Cells for Cancer Immunotherapy Published in @FrontImmunol in Immunology
#nkcells #cancerresearch #autoantibodies #biomarkers #immunology
Next Generation Natural Killer Cells for Cancer Immunotherapy
In recent years, immunotherapy for cancer has become mainstream with several products now authorized for therapeutic use in the clinic and are becomin...
bit.ly
In case you missed our #webinar on #autoantibodies as #biomarkers in immune-oncology, download here https://bit.ly/3x8VtlM
#ImmunoINSIGHTS #immunebiomarkers #clinicalresearch #immunotherapy #immunooncology
PUBLICATION #autoantibodies #immunoINSIGHTS
Paradoxical sex-specific patterns of autoantibody response to SARS-CoV-2 infection.
#ImmunoINSIGHTS #Biomarkers #immunebiomarkers #clinicalresearch #infectiousdiseases #sarscov2 #covid19
Paradoxical sex-specific patterns of autoantibody response to SARS-CoV-2 infection - Journal of Translational Medicine
Background Pronounced sex differences in the susceptibility and response to SARS-CoV-2 infection remain poorly understood. Emerging evidence has highl...
bit.ly
#ThursdayRead
Removing IL-6 from the mix prevents toxicity and boosts efficacy of checkpoint blockade
#ImmunoINSIGHTS #autoantibodies #Biomarkers #immunebiomarkers #clinicalresearch #immunooncology #checkpointinhibitors
Removing IL-6 from the mix prevents toxicity and boosts efficacy of checkpoint blockade
Immune checkpoint blockade (ICB) has two main limitations: responses vary between subgroups of patients and immune-related adverse events (irAEs) can ...
bit.ly
Interested in #autoantibody profiling?
#ImmunoINSIGHTS™ combines the most comprehensive immunogenic human antigen library + advanced analytics to support your clinical trials
#autoantibodies #immunebiomarkers #biomarkers #immunology #drugdevelopment https://t.co/ZKuXJFlVCf
What if you could access a pivotal class of #biomarkers? Learn why #Bcells and the #autoantibody repertoire is an underestimated #biomarker class to help understand the complex #immune system https://bit.ly/3xSGVas #ImmunoINSIGHTS #autoantibodies
Gallery
